Top Pharmaceutical Companies in London (117)
Cencora is a leading pharmaceutical solutions organization centered on improving the lives of people and animals everywhere. With 46,000+ global team members, we have the opportunity to make a positive impact on healthcare in communities everywhere. Our team members are empowered to activate their careers through a collective of tools and resources designed to support individual career interests and...
Cencora's Top Stability & Growth Strengths
Strong Revenue Growth: Recent results show steady top-line expansion: FY2025 rose 9.3% and FY2026 quarters continued to grow in the mid‑single digits, with full‑year guidance at 4%–6%. Management indicates both U.S. and International Healthcare Solutions are expected to expand, sustaining momentum.
Profitability: Adjusted operating income and EPS increased at double‑digit rates (e.g., FY2025 AOI +15.8% and EPS +16.3%, with Q3 FY2026 EPS +12%), and guidance points to 13%–14% adjusted operating income growth. Outlook also includes solid adjusted free cash flow of around $3.0B.
Strong Market Position & Advantage: The company is consistently portrayed as one of the three dominant U.S. pharmaceutical distributors, reflecting scale, reach, and entrenched relationships. This position supports durable volumes in specialty categories and international distribution.
Flatiron Health is a healthtech company dedicated to helping cancer centers thrive and deliver better care for patients today and tomorrow. Through clinical and data science, we translate patient experiences into real-world evidence to improve treatment, inform policy, and advance research. Cancer is smart. Together, we can be smarter. Flatiron Health is an independent affiliate of the Roche Group.
Flatiron Health's Top Stability & Growth Strengths
Market Expansion: International footprint is described as rapidly scaling, with the oncology research network tripling year over year and later noted as nearly 70% ex‑U.S. growth across the UK, Germany, Japan, and new regions like Scotland. Point‑of‑care reach is also portrayed as expanding, with 1,600+ sites of care and increases from earlier baselines.
Product Line Growth: New offerings include the launch of Flatiron Telescope and multiple AI-enabled datasets, alongside expansions of major assets such as the NSCLC Panoramic dataset. Additional capabilities like LLM-based data extraction and new hematology datasets indicate broader, monetizable product breadth.
Strategic Partnerships: Collaborations are highlighted with organizations such as NCCN, Quest Diagnostics, Candid Health, TailorMed, and DeepScribe, as well as a multi‑year partnership alongside the Paradigm transaction. Engagements with 20+ global oncology drug developers and academic institutions reinforce a partnership‑driven operating model.
Chiltern International Limited, a contract research organization, provides clinical development, scientific services.
A science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. We have three global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products. We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible, with our three global businesses, scientific and technical know-how...
GSK's Top Stability & Growth Strengths
Strong Market Position & Advantage: GSK is positioned as a top-tier global biopharmaceutical company by revenue while showing category leadership in vaccines and HIV, anchored by franchises such as Shingrix and ViiV’s portfolio. Its consistent top-10/12 standing and segment leadership in vaccines, respiratory, and HIV support a stable competitive footing.
Resilient & Sustainable Growth: Revenue and earnings momentum are supported by broad-based growth across Specialty Medicines and continued contributions from Vaccines, alongside reaffirmed multi-year sales ambitions. Guidance for continued turnover and profit expansion indicates an expectation of ongoing, steadier growth rather than a one-off spike.
Healthy Cash Flow: Operating cash generation is described as strong and is being used to fund R&D investment and shareholder returns such as dividends and buybacks. This cash profile supports resilience through investment cycles and potential volatility in specific product areas.
We are BOLDSCIENCE. We are a scientifically creative global medical communications agency. What exactly does that mean? It means our staff are made up of talented science communicators, artists, and curious disruptors, that collaborate to create impactful communication programs for pharmaceutical clients who need a compelling voice. We know what it takes to create brands, to start new conversations, to...
PPD is now part of Thermo Fisher Scientific, the world leader in serving science. Together, Thermo Fisher and PPD are creating a unique opportunity to advance their shared pursuit to enable customers to make the world healthier by accelerating the development of new medicines. We now offer a comprehensive suite of world-class services across the clinical development spectrum – from...
To create a healthier future for patients with life-threatening diseases, we are using our pioneering human extracellular matrix (ECM)-based discovery platform to develop a portfolio of programmes in fibrosis and solid tumours. Using human in vitro models that better recreate the natural cell microenvironment is transforming our ability to identify new targets, determine mechanisms of action, and increase the success...
H.E.L Group’s mission is to work together with chemistry, safety and biotechnology experts to engineer and unleash the full potential of the scientific community. To this end, H.E.L develops and manufactures innovative scientific instruments and software designed to optimize the efficiency, safety and productivity of key processes in chemistry and biology applications. The H.E.L team of 70 includes highly skilled...
Simple Pharma is the best home for proven pharma products. We provide integrated, digitally enabled, end to end operations, distribution, and compliance services to pharma companies. We’re passionate about simplifying the complex world of pharma operations to enable better access to medicines on a global scale. Simple Pharma is re-thinking the traditional sales-led model of the pharma industry by focusing...
Vitabiotics is a leading British nutraceutical company founded in 1971, specializing in the development and manufacturing of science-based vitamin and mineral supplements. Known for brands like Pregnacare, Wellman, and Perfectil, the company focuses on nutritional healthcare for various life stages. It is recognized as the UK's number one vitamin company, committed to rigorous clinical research and innovation, with a global...
ProPharma is the premier Research Consulting Organization (RCO), delivering fully customizable consulting solutions to empower biotech, med device, and pharmaceutical organizations of all sizes to advance scientific breakthroughs confidently and introduce new therapies. With over 20 years of expertise in regulatory sciences, clinical research solutions, quality & compliance, pharmacovigilance, medical information, and R&D technology, ProPharma partners with clients across the...
ProPharma's Top Stability & Growth Strengths
Market Expansion: Feedback suggests the company is broadening its global footprint, including opening a new office in Hyderabad and expanding across Central and Eastern Europe via acquisitions. These moves indicate a focus on scaling operations and accessing new markets.
Strategic Partnerships: Feedback suggests targeted acquisitions such as Clinres Farmacija and Digital Lab Consulting are used to enhance capabilities and geographic reach. These integrations appear to strengthen end-to-end service coverage across regulatory, clinical, and R&D functions.
Strong Brand Reputation: Feedback suggests multiple industry awards and recognitions, including CPHI and CRO Leadership distinctions, bolster standing as a top-tier provider. External analyst mentions, such as Everest Group’s PEAK Matrix designation, reinforce credibility.
At Eisai Inc., human health care (hhc) is our goal. We give our first thought to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative...
Eisai US's Top Stability & Growth Strengths
Strong Market Position & Advantage: Leqembi achieved the first traditional FDA approval among amyloid‑targeting antibodies with broadened Medicare coverage and a home‑use maintenance autoinjector, establishing Eisai as a front‑runner in disease‑modifying Alzheimer’s while Lenvima sustains recognized positions in select oncology indications. Feedback suggests this leadership is reinforced by Eisai leading U.S. commercial execution for Leqembi and ongoing real‑world evidence and access work.
Strong Revenue Growth: Company disclosures point to rising consolidated revenue with Leqembi cited as a key growth engine and the U.S. as its largest market, alongside sequential gains in global Leqembi sales. Evidence indicates the Americas outperformed expectations in recent quarters, with Leqembi and Lenvima highlighted as primary contributors.
Market Expansion: Regulatory and access wins such as EU approval for Leqembi, broadened U.S. Medicare coverage, and additional U.S. administration options (monthly IV maintenance and a weekly subcutaneous autoinjector) signal expanding reach. New U.S. manufacturing capacity and a built‑out Nutley HQ further support scale and market presence.
We need to shift to a world where we treat the individual, not just the disease. Our inventions work in combination with medicine to deliver personalized, optimized dosing, to provide bespoke universal healthcare access and improve outcomes for patients with chronic diseases. Closed Loop Medicine is a TechBio company developing combination prescription drug + software products, with the aim of...
Grow Pharma is the leader in supplying unlicensed cannabis medicines in the UK. Grow Pharma was established by Grow Biotech and IPS Pharma, combining cannabis sector expertise with 18 years’ experience manufacturing and importing unlicensed medicines
Almirall is a Barcelona-based global pharmaceutical company focused on medical dermatology. It partners with healthcare professionals, patients, and caregivers to understand skin disease and develop meaningful medicines and treatments. Its patient-centred research and development spans early discovery through clinical and real-world work, addressing conditions including acne, psoriasis, atopic dermatitis, actinic keratosis, alopecia, vitiligo, and hidradenitis across more than 100 countries.
For 45 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 760* high-quality generic, speciality and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 32 manufacturing plants, 8 R&D...
Founded in 1997, Ergomed is a global provider of high-quality services to the biopharmaceutical industry, spanning all phases of clinical trials, post-approval pharmacovigilance, and medical information. Ergomed’s fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, and Ergomed Clinical Research, a complete, global Phase I-IV clinical development and trial management services with...
Richmond Pharmacology is a Clinical Research Organisation run by healthcare professionals. The company works with international pharmaceutical and biotech organisations.
We are the first in class pre-clinical translational biophysics company focusing on the discovery of novel therapeutics against intrinsically disordered targets.
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. We discovered and developed the first medicines to treat the underlying cause of cystic fibrosis (CF), a rare, life-threatening genetic disease. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused...
Vertex Pharmaceuticals's Top Stability & Growth Strengths
Strong Market Position & Advantage: Company materials depict Vertex as a leader with near‑dominance in cystic fibrosis and first‑mover approvals in CRISPR‑based gene editing. This is supported by broad real‑world CF impact and landmark authorizations for Casgevy.
Strong Revenue Growth: Reported year‑over‑year revenue growth in 2025 and raised guidance for 2026 indicate ongoing momentum. Quarterly performance aligned with or exceeded guidance during the year, underscoring execution against growth plans.
Diversified Revenue Streams: Early contributions in 2025 from Alyftrek, Journavx, and Casgevy, with management signaling higher non‑CF revenues in 2026, show a broadening base beyond CF. Guidance highlighting non‑CF contribution points to increasing mix diversification over the near term.
